Navigation Links
Response Genetics Reports Second Quarter 2007 Financial Results
Date:8/19/2007

ash equivalents at June 30, 2007 were $19.4 million compared to $4.9 million at December 31, 2006. On June 8, Response Genetics completed its initial public offering of 3,000,000 shares of its common stock at a price of $7.00 per share.

Corporate Highlights

Completion of Initial Public Offering

On June 5, Response Genetics announced its initial public offering of 3,000,000 shares of its common stock at a price of $7.00 per share. Shares of Response Genetics' stock began trading on the NASDAQ under the symbol "RGDX" that day. Maxim Group LLC acted as lead underwriter and representative of the underwriters of the offering, and Caris & Company acted as co-manager.

Opening of European Laboratory in Edinburgh, Scotland

On July 2, the Company announced the opening of its first European laboratory in Edinburgh, Scotland. This is the first in a series of strategically placed global laboratories that the Company plans to open to support the pharmaceutical industry's need for genetic analysis of their global clinical trial specimens. The Edinburgh laboratory is now open, fully equipped and able to analyze clinical trial specimens.

Data Publication in Journal of Clinical Oncology

On July 9, positive Phase III clinical data results were published in the July 1 issue of the Journal of Clinical Oncology, suggesting that low expression of the biomarker Excision-Repair Cross-Complementing 1 (ERCC-1) in patient biopsies with advanced non-small cell lung cancer (NSCLC) predicts for sensitivity to cisplatin-based chemotherapy. ERCC-1 is an enzyme involved in repair of DNA strand breaks such as those caused by cisplatin. The analysis of ERCC-1 levels in this study was conducted by Response Genetics using its RGI-1 technology.

This was the first prospective study using a biomarker to predict chemotherapy response in lung cancer. These findings support the use of measurement of ERCC-1 for individualizing therapies for lung cancer patients.<
'/>"/>

SOURCE Response Genetics, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system
2. FLIPR Calcium 3 Assay Kit - An Optimal No-Wash Fluorescence Calcium Indicator Reagent for Non-Optimal Calcium Responses
3. IT critical in pandemic response, but many are not paying attention
4. Quick response manufacturing and biotech
5. Wisconsin court affirms damages in Innogenetics, Abbott patent case
6. Third Wave licenses Innogenetics tech to settle lawsuit
7. Symposium examines the effect of race on genetics and disease
8. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
9. Sonic Foundry reports GAAP loss as Q2 revenues rise
10. Fiserv reports $113.5 million in Q1 profit
11. Third Wave reports net loss of $18.9M for 2006
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... RMI specializes in Stemnexaâ„¢ ... such as meniscal tears, ACL injuries, rotator cuff ... due to degenerative conditions like osteoarthritis. Stemnexa ... promote better post-surgical outcomes. , Stemnexa combines the ... marrow harvesting with two complimentary cellular technologies: Bone ...
(Date:3/4/2015)... 2015 In an article published and posted ... Health Security review the clinical aspects of diseases caused ... bioweapons. The article, "Clinical Management of Potential Bioterrorism-Related Conditions," ... of the New England Journal of Medicine . ... , and Tom Inglesby—review the clinical management of conditions ...
(Date:3/4/2015)... N.Y. , March 4, 2015  Brooklyn residents ... their acute and chronic pain and injuries. Nunzio ... announce the grand opening of his NJS Physical Medicine ... on Thursday, March 5, 2015. Health Plus ... facility, which is located at 1178 Flatbush Avenue. This ...
(Date:3/4/2015)... Mar. 04, 2015 Research and Markets ... of Jain PharmaBiotech,s new report "Biomarkers - ... This report follows the broad ... can be objectively measured and evaluated as an ... well as pharmacological responses to a therapeutic intervention. ...
Breaking Biology Technology:Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 2Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 3Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 4Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 5Latest Clinical Information On Bioterrorism Threats 2NJS Physical Medicine & Rehabilitation Opening on Flatbush Avenue, Brooklyn, NY 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 3
... the atomic forces that cause friction, thanks to a ... Pennsylvania, the University of Houston and the U.S. Department ... by Robert Carpick of the University of Pennsylvania, found ... that had been coated with different isotopes of hydrogen ...
... CARMIEL, Israel, Nov. 2 Protalix,BioTherapeutics, Inc. (Amex: ... Aviezer,Ph.D., its President and Chief Executive Officer, will ... Conference. Dr. Aviezer,s presentation,will take place at 3:00 ... Hotel in New York City. Dr. Aviezer,s ...
... Confirmed, REINACH and BASEL, Switzerland, November 2 ... on its late-stage,investigational antibiotic iclaprim at the 9th ... VKliPha) which takes place,1-3 November in Kiel, Germany. ... substantial volume of data on iclaprim that is ...
Cached Biology Technology:Heavier hydrogen on the atomic scale reduces friction 2Protalix BioTherapeutics to Present at CIBC World Markets 18th Annual Healthcare Conference 2Arpida Presents Data on Iclaprim at Scientific Congress in Germany 2Arpida Presents Data on Iclaprim at Scientific Congress in Germany 3Arpida Presents Data on Iclaprim at Scientific Congress in Germany 4
(Date:2/5/2015)... 3, 2015 Despite a lack of ... such as consumer electronics, automotive, storage and telecommunication ... technology (SMT) screen printers. Innovations in electronics and ... push the adoption curve up. Meanwhile, sale volumes ... glue dispensers are indispensable in the production of ...
(Date:1/22/2015)... , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading source ... launch of its new website design. "When we ... infancy", says Peter O,Neill , founder and CEO of ... industry needs involvement from the key players on a very ...
(Date:1/22/2015)... , Jan. 15, 2015  BellBrook Labs, a ... discovery, announced the launch of a TR-FRET (time ... company,s Transcreener UDP Assay, a high throughput screening ... new assay will allow for sensitive detection of ...
Breaking Biology News(10 mins):End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... 2008 gets underway. Some major announcements before we hope to see ... have NOT registered please note: Online Registration closes June 30. Registration ... www.esof2008.org ESOF 2008 Press briefings in Barcelona and ... Monday July 7, 11am and in Madrid Tuesday July ...
... it erupts, drawing to it immune system cells that fight ... often leaving behind a mark or a scar. A ... there is a defect in the resolution response the ... or hardening of the arteries can result, said researchers at ...
... early targets of new trans-Pacific research using minuscule "barcodes" ... (UQ) and the University of Washington (UW) are poised ... announced $650,000 from the National and International Research Alliances ... pathogens of two debilitating mosquito-borne diseases, malaria and dengue ...
Cached Biology News:Failure to bridle inflammation spurs atherosclerosis 2
... a chemiluminescent signal enhancing reagent that ... the signal obtained with all ECL ... Plus is derived from a powerful, ... or chemiluminescent substrate enhancers, ChemiLucent™ Plus ...
... The Schleicher & Schuell BioScience Arraying ... dedicated to custom protein and nucleic ... project teams, comprised of R&D, Engineering, ... closely with collaborators every step of ...
... LC Sciences provides a genome-wide microRNA ... and proprietary probe design, which enable highly ... (1-3). We have standard arrays for mature ... latest version of the Sanger miRBase database ...
... designed for immunological studies, vaccine development, ... flexible and powerful Paraflo microfluidic on-chip ... as part of our comprehensive Epitope ... Probe Content Probe content is ...
Biology Products: